Local and circulating cytotoxic CD4+ T cells are early markers of disease activity in pediatric Crohn's disease
If validated, a blood test for cytotoxic CD4+ T cells at diagnosis could help predict who is less likely to respond to anti‑TNF drugs, potentially allowing earlier selection of alternative therapies for some children with Crohn’s disease. It may also point to IL‑27–related biology as a target for future treatments.
Pediatric patients and families, pediatric gastroenterologists, researchers studying IBD biomarkers and immune mechanisms, clinicians managing patients starting anti‑TNF therapy.
What To Know
What To Know This medRxiv preprint reports single-cell RNA sequencing of intestinal and blood T cells from treatment‑naive pediatric IBD patients and controls, identifying a population of cytotoxic CD4+ T cells (CD4 CTLs) enriched in inflamed gut tissue of Crohn’s disease and ulcerative colitis patients.
The authors link higher CD4 CTL frequencies at diagnosis — measurable in blood using a simple flow cytometry panel (CD4+ CXCR6+ CD27–) — with later poor response to anti‑TNF therapy in pediatric Crohn’s disease.
The study used an independent validation cohort, reanalysis of published datasets, and mouse experiments implicating IL‑27 in CD4 CTL differentiation; IL‑27 blockade reduced CD4 CTL formation in a mouse model. The authors propose that blood CD4 CTLs could be an early, accessible biomarker to help stratify pediatric CD patients for therapy choices.
This is a preprint (publish‑ahead‑of‑print) and the extracted content is at the abstract level; results have not completed peer review. The flow cytometry panel and association with anti‑TNF outcome are promising but preliminary and need confirmation in prospective clinical studies before changing care.
Preprint status: this work has not completed peer review. The findings are based on single‑cell profiling and associations with later treatment outcome; prospective validation in clinical trials or registries is needed before using this marker in routine treatment decisions.
